Zobrazeno 1 - 10
of 48
pro vyhledávání: '"David R. Strutton"'
Autor:
David R. Strutton, Milton C. Weinstein, Raymond Farkouh, M. Kohli, Michael Maschio, Lisa J. McGarry
Publikováno v:
Health Affairs. 34:1234-1240
In 2010 the US Advisory Committee on Immunization Practices recommended that the seven-valent pneumococcal conjugate vaccine (PCV7) be replaced by the thirteen-valent version (PCV13), which provides protection against six additional serotypes of the
Autor:
Kimberly M. Shea, Derek Weycker, David R. Strutton, Raymond Farkouh, Stephen I. Pelton, John Edelsberg
Publikováno v:
Clinical Infectious Diseases. 59:615-623
BACKGROUND In the current era of universal immunization of young children with pneumococcal conjugate vaccine, it is unclear whether the high risk ratios for pneumococcal disease previously attributed to specified chronic conditions have persisted. I
Publikováno v:
The Patient - Patient-Centered Outcomes Research. 6:125-134
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality in older adults, yet few studies have comprehensively measured the burden of CAP symptoms and their impact from the patient perspective. Our Web-survey used the newly de
Publikováno v:
Expert review of vaccines, 11(10), 1235-1247. TAYLOR & FRANCIS LTD
Currently, 13-valent pneumococcal conjugate vaccine (PCV); and ten-valent PCV vaccine are marketed. Neither vaccine obtained regulatory approval based on efficacy trials, but instead were approved based on a surrogate end point: immunogenicity data m
Autor:
Stephen I. Pelton, Derek Weycker, John Edelsberg, David R. Strutton, Raymond Farkouh, Kimberly M. Shea
Publikováno v:
BMC Health Services Research
Background The presence of certain underlying medical conditions is known to increase the risk of pneumococcal disease in persons of all ages and across a wide spectrum of conditions, as demonstrated in two recent evaluations. Corresponding estimates
Publikováno v:
Vaccine. 30:5437-5444
Background A 13-valent pneumococcal conjugate vaccine (PCV13) was recently developed for use in older adults, and may be effective not only against invasive pneumococcal disease (IPD) but also nonbacteremic pneumococcal pneumonia. The potential publi
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands
Autor:
Raymond Farkouh, Sharon Hwang, David R. Strutton, Sotiria Papanicolaou, Stephanie R. Earnshaw, Rogier M. Klok, Stathis Kontodimas, Ulrike Theidel
Publikováno v:
Journal of Infection. 64:54-67
Summary Background Seven-valent pneumococcal conjugate vaccine (PCV7) had profound public-health impacts and is considered cost-effective and potentially cost saving. Two new PCVs have been launched, a 10-valent vaccine (PCV10) and a 13-valent vaccin
Publikováno v:
Value in Health. 14(5):S65-S70
Objectives: Vaccination is an effective intervention for reduce child morbidity and mortality associated to pneumococcus. The availability of new anti-pneumococcal vaccines makes it necessary to evaluate its potential impact on public health and cost
Autor:
David R. Strutton, Jaime L. Rubin, Lisa J. McGarry, K Gilmore, Milton C. Weinstein, Stephen I. Pelton, Keith P. Klugman
Publikováno v:
Vaccine. 28:7634-7643
The 7-valent pneumococcal conjugate vaccine (PCV7) has dramatically decreased pneumococcal disease incidence, and the 13-valent vaccine (PCV13) protects against 6 additional Streptococcus pneumoniae serotypes. A decision-analytic model was constructe
Publikováno v:
Vaccine. 28:4955-4960
We developed a model characterizing rates and costs of pneumococcal disease in the US to estimate the expected annual clinical and economic burden of this condition among older adults. Among the 91.5 million US adults aged >or=50 years, 29,500 cases